BECN1 and breast carcinoma: For example, in ER (estrogen receptor)-positive breast cancer cells, suppressing beclin-1 boosted tamoxifen sensitivity in vitro, and lower beclin-1 expression predicts a better prognosis in patients with ER-positive breast cancer [526].